Cargando…
Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study
Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory prospective observational study to compare th...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793345/ https://www.ncbi.nlm.nih.gov/pubmed/35097130 http://dx.doi.org/10.1155/2022/5603864 |
_version_ | 1784640577955954688 |
---|---|
author | Oe, Yuki Nomoto, Hiroshi Nakamura, Akinobu Kuwabara, Saki Takahashi, Yuka Yasui, Ayano Izumihara, Rimi Miya, Aika Kameda, Hiraku Cho, Kyu Yong Atsumi, Tatsuya Miyoshi, Hideaki |
author_facet | Oe, Yuki Nomoto, Hiroshi Nakamura, Akinobu Kuwabara, Saki Takahashi, Yuka Yasui, Ayano Izumihara, Rimi Miya, Aika Kameda, Hiraku Cho, Kyu Yong Atsumi, Tatsuya Miyoshi, Hideaki |
author_sort | Oe, Yuki |
collection | PubMed |
description | Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory prospective observational study to compare the effect of IDegLira and the combination on GV. We recruited hospitalized patients with type 2 diabetes who had stable glycemic control with insulin degludec (≤16 units/day) and taking a DPP-4 inhibitor. GV was analyzed using continuous glucose monitoring (CGM) before and after switching the medication to IDegLira. The principal endpoint was the change in mean amplitude of glycemic excursions (MAGE). Other indices of GV and CGM parameters were analyzed as the secondary endpoints. Fifteen participants were enrolled and 12 completed the study. In these participants, the DPP-4 inhibitor and insulin degludec were discontinued, and the equivalent dose of IDegLira was commenced. Switching to IDegLira significantly improved MAGE from 74.9 (60.3, 97.7) mg/dL to 64.8 (52.0, 78.2) mg/dL (P < 0.05), as well as other indices of GV and 24-hour mean blood glucose concentration. Analysis of the ambulatory glucose profile showed marked reductions in postprandial glucose concentration. Nocturnal glucose concentration was similar under the two treatment regimens. IDegLira improved GV as well as the mean and the postprandial glucose concentration by switching from insulin degludec plus DPP-4 inhibitor combination. IDegLira might be beneficial for patients being treated with low-dose basal insulin. |
format | Online Article Text |
id | pubmed-8793345 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-87933452022-01-28 Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study Oe, Yuki Nomoto, Hiroshi Nakamura, Akinobu Kuwabara, Saki Takahashi, Yuka Yasui, Ayano Izumihara, Rimi Miya, Aika Kameda, Hiraku Cho, Kyu Yong Atsumi, Tatsuya Miyoshi, Hideaki J Diabetes Res Research Article Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory prospective observational study to compare the effect of IDegLira and the combination on GV. We recruited hospitalized patients with type 2 diabetes who had stable glycemic control with insulin degludec (≤16 units/day) and taking a DPP-4 inhibitor. GV was analyzed using continuous glucose monitoring (CGM) before and after switching the medication to IDegLira. The principal endpoint was the change in mean amplitude of glycemic excursions (MAGE). Other indices of GV and CGM parameters were analyzed as the secondary endpoints. Fifteen participants were enrolled and 12 completed the study. In these participants, the DPP-4 inhibitor and insulin degludec were discontinued, and the equivalent dose of IDegLira was commenced. Switching to IDegLira significantly improved MAGE from 74.9 (60.3, 97.7) mg/dL to 64.8 (52.0, 78.2) mg/dL (P < 0.05), as well as other indices of GV and 24-hour mean blood glucose concentration. Analysis of the ambulatory glucose profile showed marked reductions in postprandial glucose concentration. Nocturnal glucose concentration was similar under the two treatment regimens. IDegLira improved GV as well as the mean and the postprandial glucose concentration by switching from insulin degludec plus DPP-4 inhibitor combination. IDegLira might be beneficial for patients being treated with low-dose basal insulin. Hindawi 2022-01-19 /pmc/articles/PMC8793345/ /pubmed/35097130 http://dx.doi.org/10.1155/2022/5603864 Text en Copyright © 2022 Yuki Oe et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Oe, Yuki Nomoto, Hiroshi Nakamura, Akinobu Kuwabara, Saki Takahashi, Yuka Yasui, Ayano Izumihara, Rimi Miya, Aika Kameda, Hiraku Cho, Kyu Yong Atsumi, Tatsuya Miyoshi, Hideaki Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study |
title | Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study |
title_full | Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study |
title_fullStr | Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study |
title_full_unstemmed | Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study |
title_short | Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study |
title_sort | switching from insulin degludec plus dipeptidyl peptidase-4 inhibitor to insulin degludec/liraglutide improves glycemic variability in patients with type 2 diabetes: a preliminary prospective observation study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793345/ https://www.ncbi.nlm.nih.gov/pubmed/35097130 http://dx.doi.org/10.1155/2022/5603864 |
work_keys_str_mv | AT oeyuki switchingfrominsulindegludecplusdipeptidylpeptidase4inhibitortoinsulindegludecliraglutideimprovesglycemicvariabilityinpatientswithtype2diabetesapreliminaryprospectiveobservationstudy AT nomotohiroshi switchingfrominsulindegludecplusdipeptidylpeptidase4inhibitortoinsulindegludecliraglutideimprovesglycemicvariabilityinpatientswithtype2diabetesapreliminaryprospectiveobservationstudy AT nakamuraakinobu switchingfrominsulindegludecplusdipeptidylpeptidase4inhibitortoinsulindegludecliraglutideimprovesglycemicvariabilityinpatientswithtype2diabetesapreliminaryprospectiveobservationstudy AT kuwabarasaki switchingfrominsulindegludecplusdipeptidylpeptidase4inhibitortoinsulindegludecliraglutideimprovesglycemicvariabilityinpatientswithtype2diabetesapreliminaryprospectiveobservationstudy AT takahashiyuka switchingfrominsulindegludecplusdipeptidylpeptidase4inhibitortoinsulindegludecliraglutideimprovesglycemicvariabilityinpatientswithtype2diabetesapreliminaryprospectiveobservationstudy AT yasuiayano switchingfrominsulindegludecplusdipeptidylpeptidase4inhibitortoinsulindegludecliraglutideimprovesglycemicvariabilityinpatientswithtype2diabetesapreliminaryprospectiveobservationstudy AT izumihararimi switchingfrominsulindegludecplusdipeptidylpeptidase4inhibitortoinsulindegludecliraglutideimprovesglycemicvariabilityinpatientswithtype2diabetesapreliminaryprospectiveobservationstudy AT miyaaika switchingfrominsulindegludecplusdipeptidylpeptidase4inhibitortoinsulindegludecliraglutideimprovesglycemicvariabilityinpatientswithtype2diabetesapreliminaryprospectiveobservationstudy AT kamedahiraku switchingfrominsulindegludecplusdipeptidylpeptidase4inhibitortoinsulindegludecliraglutideimprovesglycemicvariabilityinpatientswithtype2diabetesapreliminaryprospectiveobservationstudy AT chokyuyong switchingfrominsulindegludecplusdipeptidylpeptidase4inhibitortoinsulindegludecliraglutideimprovesglycemicvariabilityinpatientswithtype2diabetesapreliminaryprospectiveobservationstudy AT atsumitatsuya switchingfrominsulindegludecplusdipeptidylpeptidase4inhibitortoinsulindegludecliraglutideimprovesglycemicvariabilityinpatientswithtype2diabetesapreliminaryprospectiveobservationstudy AT miyoshihideaki switchingfrominsulindegludecplusdipeptidylpeptidase4inhibitortoinsulindegludecliraglutideimprovesglycemicvariabilityinpatientswithtype2diabetesapreliminaryprospectiveobservationstudy |